Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8576301 | 0.93 | ALDH1A1 (0.62) | ALDH1A1HSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL56599 | 0.92 | ALDH1A1 (0.65) | ALDH1A1HSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL10633314 | 0.86 | ALDH1A1 (0.51) | ALDH1A1HSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL1134304 | 0.81 | CA2 (0.77) | ALDH1A1HSD17B10TDP1LMNACA1 | |
| SCHEMBL364561 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL6514924 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL10408548 | 0.80 | ALDH1A1 (0.56) | ALDH1A1HSD17B10TDP1LMNANPC1 | |
| SCHEMBL28709181 | 0.79 | HTR6 (0.78) | ALDH1A1HSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL9140147 | 0.79 | HTR6 (0.78) | ALDH1A1HSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL16000 | 0.78 | ALDH1A1 (0.54) | ALDH1A1HSD17B10TDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445440-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2539333-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104266-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-08-25 | — | — | US | disclosed |
| EP-0019899-B1 | DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS MEDICINES AND IN ANIMAL FOOD | BAYER AG (DE) | 1984-07-18 | — | — | EP | disclosed |
| US-4388246-A | THERMAL SPLITTING OF CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
| EP-0019899-A1 | Derivatives of 3,4,5-trihydroxypiperidine, processes for their preparation, and their use as medicines and in animal food | BAYER AG (DE) | 1980-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | ALDH1A1 4127/4885HSD17B10 3955/4885TDP1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.